MTOR and lung cancer: Of note, the use of CDK4/6 inhibitors in combination with mitogen-activated extracellular signal-regulated kinase (MEK), or mammalian target of rapamycin (mTOR) inhibitors for treating lung cancer are being tested in clinical trials (NCT03170206, NCT02857270).